Member Info for Dollyg

@runnerrunner

Isn't unproven biotech all about assumptions???? Until the data lands that is all anyone has.

Thanks Aldebaran.

I am hopping for £25 a share.

Would the board go for a take over now? Might be selling the company short.

Patience is a virtue I lack however I have resisted cashing in because in the mid term this looks very exciting.

Speaking to an oil trader friend, ( yes different game I know) He said of biotech its a game of nerves. Nobody wants to spend too much too early on something that shows promise but without as much confirmation data as possible but nor do they want to have to spend gargantuan amounts if they mis judge the timing. He said sometimes success depends on the nature of the risk willing to be taken. Someone will strike at the end of the first 1/4.

Sit and be patient seems the order of the day.

I asked AI the potentials of a buyout. Results blew ne away.

Thank you

Be good to get a medically qualified opinion of the ACTUAL potential of how many differing treatments this technology could affect.

I read the £3 billion figure was first mooted in 2023 and they seem to have come a long way since then in terms of efficacy. The concensus seens to be wait.

Thank you.

Given that the latest news seems to be that Avactas products can be applied to almost any drug. Would that not be a seismic shift in the meathod to treat a multiple of illnesses? Not just cancer?